BenevolentAI looks to artificial intelligence for speedy development of in-licensed drugs

#artificialintelligence

A key ambition of BenevolentAI is to utilize artificial intelligence in revolutionizing the drug development process. Now, with a licensing agreement with Janssen, it is one significant step closer to realizing that dream. With assistance from Johnson & Johnson Innovation's Centre in London, the British AI company has acquired an undisclosed number of novel clinical stage drug candidates, together with their related patents. The company used its AI platform to evaluate the potential of these small molecule compounds and found some could be promising candidates for hard-to-treat diseases. "The compounds come with a wealth of clinical and biological data that enables BenevolentAI to have further insights into the biology of diseases," said BenevolentAI Bio's CEO Jackie Hunter.


BenevolentBio takes the AI road

#artificialintelligence

London-based biotech business BenevolentBio is on a mission to overcome the failure of the drug industry to innovate on drug discovery. Andrew Huddart explains and talks to its chief executive, Jackie Hunter. The tools of big data are helping to reshape the industrial landscape of the 21st century. They are helping make entire economic activities obsolete and helping give rise to new ones. The area of health and drug discovery in particular is far from excluded from this change.


Turning rare diseases into efficient targets with AI

#artificialintelligence

BenevolentBio's CMO, Dr Patrick Keohane, says the industry is on the cusp of an artificial intelligence (AI) revolution… Medical research is entering a period of rapid transformation, driven by the explosion of scientific data, rapid advances in artificial intelligence (AI), and the development of extremely powerful computers. This convergence enables researchers to access enormous and diverse datasets to rapidly form and test scientific hypotheses. It is disrupting the way we identify, validate, and transform scientific concepts into potential Healthcare solutions – ultimately revolutionising the scientific process. AI enables access and the more effective use of existing information for the discovery and development of better drugs at a speed previously unimagined. This is helping to meet the high demand from society to provide better medicines at a reasonable cost, but also influencing how we are looking to treat rarer forms of disease.


AI Scientist

#artificialintelligence

BenevolentAI, founded in 2013, creates and applies AI technologies to transform the way medicines are discovered and developed. BenevolentAI seeks to improve patient's lives by applying technology designed to generate better data decision making and in doing so lower drug development costs, decrease failure rates and increase the speed at which medicines are generated. The company has developed the Benevolent Platform - a discovery platform used by BenevolentAI scientists to find new ways to treat disease and personalise drugs to patients. BenevolentAI is HQ'd in London with a research facility in Cambridge (UK) and further offices in New York and Antwerp. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson's, Ulcerative Colitis and Sarcopenia.


Research Engineer

#artificialintelligence

BenevolentAI, founded in 2013, creates and applies AI technologies to transform the way medicines are discovered and developed. BenevolentAI seeks to improve patient's lives by applying technology designed to generate better data decision making and in doing so lower drug development costs, decrease failure rates and increase the speed at which medicines are generated. The company has developed the Benevolent Platform - a discovery platform used by BenevolentAI scientists to find new ways to treat disease and personalise drugs to patients. BenevolentAI is HQ'd in London with a research facility in Cambridge (UK) and further offices in New York and Antwerp. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson's, Ulcerative Colitis and Sarcopenia.